In Washington, even widely hailed programs with bipartisan support — like the rare pediatric disease priority review voucher ...

Meeting to be held in Boston on April 8 and in New York on April 9 hosted by Piper Sandler.Stay Ahead of the Market: Discover outperforming ...

For decades, the pharmaceutical industry has been defined by groundbreaking medical discoveries. But today, some of it ...

TD Cowen analyst Tyler Van Buren maintained a Buy rating on NewAmsterdam Pharma Company (NAMS – Research Report) today. The company’s shares ...

When a pharmaceutical company receives FDA approval for a new therapy, it marks the culmination of years—often over a ...

Funds have also been suspended for AIDS Clinical Trial Group, a nearly 40-year-old system that has been responsible for key ...

March 24, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The FDA has approved BridgeBio Pharma's acoramidis for life-threatening heart disorder transthyretin amyloidosis cardiomyopathy (ATTR-CM), setting up a market showdown with its larger rival Pfizer.

BridgeBio Pharma has raised $250 million from the sale of nine million shares that is earmarked for the commercial launch of its acoramidis drug for transthyretin amyloidosis (ATTR) cardiomyopathy.

Evercore ISI sees cheap buying opportunities in various stock market sectors as the trade war sends stocks into a bear market ...

The "Enterprise Tech Ecosystem Series: AIG 2025" company profile has been added to ResearchAndMarkets.com's offering. The report provides insights into AIG's tech activities, including its digital ...